[Treat flap ischemia-reperfusion injury by local transplanting human umbilical cord mesenchymal stem cells].
To explore the possibilities of human umbilical cord mesenchymal stem cells (HUC-MSCs) differentiate into vascular endothelial cells, thus to treat flap ischemic reperfusion injury and then promote the flap survival. HUC-MSCs in vitro, and flow cytometric identification. Labeling stem cells with EdU, and then transplant stem cells into local of ischemia-reperfusion injury flap of rats (treatment group) , setting PBS control group. Observe the flap survival rate 7 days after, and execute rats. Take flap tissues for pathological sections, and detect vascular endothelial growth factor (VEGF) by immunohistochemical staining, detect the distribution or differentiation of the donor cells in cell receptor by EdU fluorescent staining. 7 days after, the flap survival rate of treatment group was (97.58 +/- 3.41)%, the flap survival rate of control group was (54.37 +/- 8.78)%, the rate of treatment group was higher than control group (P < 0.05). The density of micrangium and VEGF of treatment group was higher than control group obviously (P < 0.05). The continuous distribution of positive cells that labeled with EdU were found in new vascular endothelial of treatment group' s survival flap tissues. HUC-MSCs could differentiate into vascular endothelial cells, directly involved in generating new blood vesselsand, additionally could increase expression of VEGF to promote the formation of new blood vessels, then to set up the new micro circulation, accordingly to treat flap ischemic reperfusion injury and then promote the flap survival.